Cardiotoxicity associated with bortezomib: A single-center experience
Studies evaluating the prevalence of cardiotoxicity associated with bortezomib are limited. We proposed this study to evaluate the prevalence of cardiotoxicity associated with bortezomib and its relation to multiple myeloma and other malignancies. This is a retrospective, chart review study. Subject...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and therapeutics 2017-10, Vol.13 (6), p.961-963 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 963 |
|---|---|
| container_issue | 6 |
| container_start_page | 961 |
| container_title | Journal of cancer research and therapeutics |
| container_volume | 13 |
| creator | Gurram, Murali Krishna Pulivarthi, Swaroopa Ehresmann, Kirsten Mathew, Josy |
| description | Studies evaluating the prevalence of cardiotoxicity associated with bortezomib are limited. We proposed this study to evaluate the prevalence of cardiotoxicity associated with bortezomib and its relation to multiple myeloma and other malignancies.
This is a retrospective, chart review study. Subjects who received bortezomib at the HealthEast care system for various oncologic conditions were evaluated after obtaining IRB approval.
A total of 64 patients received bortezomib for various malignancies. Nine out of 64 (14%) patients developed cardiotoxicity during treatment with bortezomib, and the majority of these patients had a prior cardiac history and other cardiac risk factors. On further review, we did not find any significant causal relationship between these cardiac events and bortezomib.
Cardiotoxicity is probably not related to bortezomib, even though there are some case reports suggestive of cardiac events related to bortezomib. Our findings need to be confirmed in multicenter, prospective studies. |
| doi_str_mv | 10.4103/0973-1482.172126 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1977205895</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A519529467</galeid><sourcerecordid>A519529467</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-10cd9bbd17fb0b8114e97e37e7d25310364a914f3f434334b6d7208e81836e713</originalsourceid><addsrcrecordid>eNptkctLxDAQxoMouj7unqTgxUvXTJI2ibdl8QWCFz2XNJ2ukbZZkyw-_norvlCWOQzM_L6PbxhCDoFOBVB-SrXkOQjFpiAZsHKDTEBrlQvgapNMftY7ZDfGR0oLyZjaJjtMMy51oSfkfG5C43zyL8669JqZGL11JmGTPbv0kNU-JHzzvavPslkW3bDoMLc4JAwZviwxOBws7pOt1nQRD776Hrm_OL-bX-U3t5fX89lNbrmGlAO1ja7rBmRb01oBCNQSuUTZsIKPB5XCaBAtbwUXnIu6bCSjChUoXqIEvkdOPn2XwT-tMKaqd9Fi15kB_SpWoOUoKJQuRvT4H_roV2EY031QqpCasvKXWpgOKze0PgVjP0yrWQG6YFqUcqTyNdQCBwym8wO2bhz_4adr-LEa7J1dKzj6Cruqe2yqZXC9Ca_V95_4OyJvkNs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1978579026</pqid></control><display><type>article</type><title>Cardiotoxicity associated with bortezomib: A single-center experience</title><source>MEDLINE</source><source>Medknow Open Access Medical Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Gurram, Murali Krishna ; Pulivarthi, Swaroopa ; Ehresmann, Kirsten ; Mathew, Josy</creator><creatorcontrib>Gurram, Murali Krishna ; Pulivarthi, Swaroopa ; Ehresmann, Kirsten ; Mathew, Josy</creatorcontrib><description>Studies evaluating the prevalence of cardiotoxicity associated with bortezomib are limited. We proposed this study to evaluate the prevalence of cardiotoxicity associated with bortezomib and its relation to multiple myeloma and other malignancies.
This is a retrospective, chart review study. Subjects who received bortezomib at the HealthEast care system for various oncologic conditions were evaluated after obtaining IRB approval.
A total of 64 patients received bortezomib for various malignancies. Nine out of 64 (14%) patients developed cardiotoxicity during treatment with bortezomib, and the majority of these patients had a prior cardiac history and other cardiac risk factors. On further review, we did not find any significant causal relationship between these cardiac events and bortezomib.
Cardiotoxicity is probably not related to bortezomib, even though there are some case reports suggestive of cardiac events related to bortezomib. Our findings need to be confirmed in multicenter, prospective studies.</description><identifier>ISSN: 0973-1482</identifier><identifier>EISSN: 1998-4138</identifier><identifier>DOI: 10.4103/0973-1482.172126</identifier><identifier>PMID: 29237959</identifier><language>eng</language><publisher>India: Medknow Publications and Media Pvt. Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Bortezomib ; Bortezomib - administration & dosage ; Bortezomib - adverse effects ; Cancer ; Cardiotoxicity - diagnosis ; Cardiotoxicity - etiology ; Cardiotoxicity - pathology ; Cardiovascular disease ; Cardiovascular diseases ; Care and treatment ; Chemotherapy ; Complications and side effects ; Development and progression ; Female ; Health risk assessment ; Heart - drug effects ; Heart - physiopathology ; Heart failure ; Humans ; Inhibitor drugs ; Male ; Middle Aged ; Multiple myeloma ; Multiple Myeloma - complications ; Multiple Myeloma - drug therapy ; Multiple Myeloma - pathology ; Neoplasm Recurrence, Local ; Patients ; Peripheral neuropathy ; Retrospective Studies ; Systematic review ; Targeted cancer therapy ; Tumors</subject><ispartof>Journal of cancer research and therapeutics, 2017-10, Vol.13 (6), p.961-963</ispartof><rights>COPYRIGHT 2017 Medknow Publications and Media Pvt. Ltd.</rights><rights>Copyright Medknow Publications & Media Pvt. Ltd. Oct/Dec 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-10cd9bbd17fb0b8114e97e37e7d25310364a914f3f434334b6d7208e81836e713</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29237959$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gurram, Murali Krishna</creatorcontrib><creatorcontrib>Pulivarthi, Swaroopa</creatorcontrib><creatorcontrib>Ehresmann, Kirsten</creatorcontrib><creatorcontrib>Mathew, Josy</creatorcontrib><title>Cardiotoxicity associated with bortezomib: A single-center experience</title><title>Journal of cancer research and therapeutics</title><addtitle>J Cancer Res Ther</addtitle><description>Studies evaluating the prevalence of cardiotoxicity associated with bortezomib are limited. We proposed this study to evaluate the prevalence of cardiotoxicity associated with bortezomib and its relation to multiple myeloma and other malignancies.
This is a retrospective, chart review study. Subjects who received bortezomib at the HealthEast care system for various oncologic conditions were evaluated after obtaining IRB approval.
A total of 64 patients received bortezomib for various malignancies. Nine out of 64 (14%) patients developed cardiotoxicity during treatment with bortezomib, and the majority of these patients had a prior cardiac history and other cardiac risk factors. On further review, we did not find any significant causal relationship between these cardiac events and bortezomib.
Cardiotoxicity is probably not related to bortezomib, even though there are some case reports suggestive of cardiac events related to bortezomib. Our findings need to be confirmed in multicenter, prospective studies.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Bortezomib</subject><subject>Bortezomib - administration & dosage</subject><subject>Bortezomib - adverse effects</subject><subject>Cancer</subject><subject>Cardiotoxicity - diagnosis</subject><subject>Cardiotoxicity - etiology</subject><subject>Cardiotoxicity - pathology</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Complications and side effects</subject><subject>Development and progression</subject><subject>Female</subject><subject>Health risk assessment</subject><subject>Heart - drug effects</subject><subject>Heart - physiopathology</subject><subject>Heart failure</subject><subject>Humans</subject><subject>Inhibitor drugs</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - complications</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Multiple Myeloma - pathology</subject><subject>Neoplasm Recurrence, Local</subject><subject>Patients</subject><subject>Peripheral neuropathy</subject><subject>Retrospective Studies</subject><subject>Systematic review</subject><subject>Targeted cancer therapy</subject><subject>Tumors</subject><issn>0973-1482</issn><issn>1998-4138</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkctLxDAQxoMouj7unqTgxUvXTJI2ibdl8QWCFz2XNJ2ukbZZkyw-_norvlCWOQzM_L6PbxhCDoFOBVB-SrXkOQjFpiAZsHKDTEBrlQvgapNMftY7ZDfGR0oLyZjaJjtMMy51oSfkfG5C43zyL8669JqZGL11JmGTPbv0kNU-JHzzvavPslkW3bDoMLc4JAwZviwxOBws7pOt1nQRD776Hrm_OL-bX-U3t5fX89lNbrmGlAO1ja7rBmRb01oBCNQSuUTZsIKPB5XCaBAtbwUXnIu6bCSjChUoXqIEvkdOPn2XwT-tMKaqd9Fi15kB_SpWoOUoKJQuRvT4H_roV2EY031QqpCasvKXWpgOKze0PgVjP0yrWQG6YFqUcqTyNdQCBwym8wO2bhz_4adr-LEa7J1dKzj6Cruqe2yqZXC9Ca_V95_4OyJvkNs</recordid><startdate>201710</startdate><enddate>201710</enddate><creator>Gurram, Murali Krishna</creator><creator>Pulivarthi, Swaroopa</creator><creator>Ehresmann, Kirsten</creator><creator>Mathew, Josy</creator><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications & Media Pvt. Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>201710</creationdate><title>Cardiotoxicity associated with bortezomib: A single-center experience</title><author>Gurram, Murali Krishna ; Pulivarthi, Swaroopa ; Ehresmann, Kirsten ; Mathew, Josy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-10cd9bbd17fb0b8114e97e37e7d25310364a914f3f434334b6d7208e81836e713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Bortezomib</topic><topic>Bortezomib - administration & dosage</topic><topic>Bortezomib - adverse effects</topic><topic>Cancer</topic><topic>Cardiotoxicity - diagnosis</topic><topic>Cardiotoxicity - etiology</topic><topic>Cardiotoxicity - pathology</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Complications and side effects</topic><topic>Development and progression</topic><topic>Female</topic><topic>Health risk assessment</topic><topic>Heart - drug effects</topic><topic>Heart - physiopathology</topic><topic>Heart failure</topic><topic>Humans</topic><topic>Inhibitor drugs</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - complications</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Multiple Myeloma - pathology</topic><topic>Neoplasm Recurrence, Local</topic><topic>Patients</topic><topic>Peripheral neuropathy</topic><topic>Retrospective Studies</topic><topic>Systematic review</topic><topic>Targeted cancer therapy</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gurram, Murali Krishna</creatorcontrib><creatorcontrib>Pulivarthi, Swaroopa</creatorcontrib><creatorcontrib>Ehresmann, Kirsten</creatorcontrib><creatorcontrib>Mathew, Josy</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cancer research and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gurram, Murali Krishna</au><au>Pulivarthi, Swaroopa</au><au>Ehresmann, Kirsten</au><au>Mathew, Josy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cardiotoxicity associated with bortezomib: A single-center experience</atitle><jtitle>Journal of cancer research and therapeutics</jtitle><addtitle>J Cancer Res Ther</addtitle><date>2017-10</date><risdate>2017</risdate><volume>13</volume><issue>6</issue><spage>961</spage><epage>963</epage><pages>961-963</pages><issn>0973-1482</issn><eissn>1998-4138</eissn><abstract>Studies evaluating the prevalence of cardiotoxicity associated with bortezomib are limited. We proposed this study to evaluate the prevalence of cardiotoxicity associated with bortezomib and its relation to multiple myeloma and other malignancies.
This is a retrospective, chart review study. Subjects who received bortezomib at the HealthEast care system for various oncologic conditions were evaluated after obtaining IRB approval.
A total of 64 patients received bortezomib for various malignancies. Nine out of 64 (14%) patients developed cardiotoxicity during treatment with bortezomib, and the majority of these patients had a prior cardiac history and other cardiac risk factors. On further review, we did not find any significant causal relationship between these cardiac events and bortezomib.
Cardiotoxicity is probably not related to bortezomib, even though there are some case reports suggestive of cardiac events related to bortezomib. Our findings need to be confirmed in multicenter, prospective studies.</abstract><cop>India</cop><pub>Medknow Publications and Media Pvt. Ltd</pub><pmid>29237959</pmid><doi>10.4103/0973-1482.172126</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0973-1482 |
| ispartof | Journal of cancer research and therapeutics, 2017-10, Vol.13 (6), p.961-963 |
| issn | 0973-1482 1998-4138 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1977205895 |
| source | MEDLINE; Medknow Open Access Medical Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Bortezomib Bortezomib - administration & dosage Bortezomib - adverse effects Cancer Cardiotoxicity - diagnosis Cardiotoxicity - etiology Cardiotoxicity - pathology Cardiovascular disease Cardiovascular diseases Care and treatment Chemotherapy Complications and side effects Development and progression Female Health risk assessment Heart - drug effects Heart - physiopathology Heart failure Humans Inhibitor drugs Male Middle Aged Multiple myeloma Multiple Myeloma - complications Multiple Myeloma - drug therapy Multiple Myeloma - pathology Neoplasm Recurrence, Local Patients Peripheral neuropathy Retrospective Studies Systematic review Targeted cancer therapy Tumors |
| title | Cardiotoxicity associated with bortezomib: A single-center experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T06%3A08%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cardiotoxicity%20associated%20with%20bortezomib:%20A%20single-center%20experience&rft.jtitle=Journal%20of%20cancer%20research%20and%20therapeutics&rft.au=Gurram,%20Murali%20Krishna&rft.date=2017-10&rft.volume=13&rft.issue=6&rft.spage=961&rft.epage=963&rft.pages=961-963&rft.issn=0973-1482&rft.eissn=1998-4138&rft_id=info:doi/10.4103/0973-1482.172126&rft_dat=%3Cgale_proqu%3EA519529467%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1978579026&rft_id=info:pmid/29237959&rft_galeid=A519529467&rfr_iscdi=true |